On September 25, 2025, the BSI Medical Society Journal Club, hosted by Bob Kaplan with contributions from Pete Shaw, continued their exploration of redox biology. In this session they turn from insulin resistance to the broader Reactive Oxygen Species (ROS) Hypothesis of Obesity, based on theories by Peter Dobromylskyj. The discussion built on prior Journal Clubs reviewing “Insulin Resistance as a Cellular Antioxidant Defense Mechanism” and “ROS Are Good,” tracing how mitochondrial signaling may regulate nutrient handling and fat storage. Bob outlined how ROS, long viewed as harmful byproducts, act as ancient, essential metabolic signals that coordinate energy flux between the mitochondria and the cell. When dietary fats—particularly linoleic acid–rich seed oils—lower ROS generation, the mitochondria’s “brake” on insulin signaling weakens. Cells remain insulin-sensitive longer than they should, driving continued nutrient uptake and fat accumulation. Within this framing, obesity represents a failure to generate adequate ROS at the right time—a redox imbalance rather than a simple surplus of calories.
Expanding the concept, Bob and Pete positioned the ROS model within a hierarchy of metabolic theories—from the carbohydrate-insulin and fuel-partitioning frameworks to the broader evolutionary mismatch between ancestral diets and modern food environments. They argued that polyunsaturated fats, through their dampening effect on mitochondrial ROS, create an inappropriate state of cellular energy oversupply that promotes insulin sensitivity when resistance would normally act as a protective feedback. In contrast, saturated fats generate sufficient ROS to signal satiety at the mitochondrial level, aligning energy intake with demand. Bob and Pete emphasized that this perspective reframes “seed oil harm” as a redox signaling problem rather than an inflammatory one and may explain why high-fat ancestral diets or ketogenic approaches restore metabolic balance. Participants reflected on how these ideas challenge conventional obesity models, offering a unifying mechanism that connects nutrient composition, mitochondrial signaling, and the physiology of energy storage.
The archive of this BSI Journal Club is available here free, for anyone, while most Club meetings are only available for Medical Society Members and MetFix affiliates, in their dashboard.
Bob Kaplan is an independent research analyst. Bob previously served as director of research at Early Medical, contributing to The Drive podcast with Peter Attia and its other properties. Kaplan was a researcher at the Nutrition Science Initiative (NuSI), and an exercise physiologist at the University of Nevada, Las Vegas. His current and previous research interests include meta-research, chronic diseases, bioenergetics, exercise physiology, and nutrition.
Support the Broken Science Initiative.
Subscribe today →
2 Comments
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
So good. Thanks, guys.
Thank you for continuing to speak about ROS theory. Going to the Foundations Course opened my eyes to the issue. The continued discussion helps gives me the tools in my affiliate to further help educate my members